initial public offerings (IPOs) trading on American exchanges

Thursday, July 31, 2014

Synchrony Financial (SYF) began trading on the NYSE on 31 July 2014

President and CEO Margaret Keane of Synchrony Financial rings the Opening Bell at The New York Stock Exchange on July 31, 2014

Synchrony Financial (Synchrony) is a consumer financial services companies in the United States. The Company provides a range of credit products through programs it has established with a diverse group of national and regional retailers, local merchants, manufacturers, buying groups, industry associations and healthcare service providers. The Company offers its credit products primarily through its wholly owned subsidiary, Synchrony Bank (previously known as GE Capital Retail Bank) (the Bank). Through the Bank, it offers, directly to retail and commercial customers, a range of deposit products insured by the Federal Deposit Insurance Corporation (FDIC), including certificates of deposit, individual retirement accounts (IRAs), money market accounts and savings accounts, under its Optimizer brand. It also takes deposits at the Bank through third-party securities brokerage firms that offer its FDIC-insured deposit products to their customers.


777 Long Ridge Rd
STAMFORD, CT 06902-1250
United States 

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin19.52%17.88%
Operating margin31.14%28.38%
EBITD margin-32.64%
Return on average assets3.78%3.52%
Return on average equity37.30%37.55%

Sunday, July 27, 2014

Advanced Drainage Systems (WMS) began trading on the NYSE on 25 July 2014

The Hilliard, Ohio-based company makes water drainage systems and pipes. It raised $232 million after the company and some of its shareholders sold 14.5 million shares for $16 per share, which was below its previously expected range between $17 and $19 per share. Advanced Drainage plans to use some of the money raised to pay its debt. Its shares, which are trading on the New York Stock Exchange under the symbol "WMS," rose 15 cents to close at $16.15.


Advanced Drainage Systems, Inc. is a manufacturer of thermoplastic corrugated pipe, providing a comprehensive suite of water management products and superior drainage solutions for use in the construction and infrastructure marketplace. The Company’s products are used across a range of end markets and applications, including non-residential, residential, agriculture and infrastructure applications. The Company’s product line includes corrugated high density polyethylene (HDPE) pipe, polypropylene (PP) pipe and related water management products. The Company has a domestic network of 48 manufacturing plants and 19 distribution centers allowing it to effectively serve all markets in the United States, which it defines as the largest 100 metropolitan statistical areas based on population.


4640 Trueman Boulevard
United States

Key stats and ratios

Q1 (Mar '14)2014
Net profit margin-6.02%1.35%
Operating margin-13.88%4.99%
EBITD margin-9.72%
Return on average assets-4.80%1.57%
Return on average equity--

Saturday, July 26, 2014

Innocoll (INNL) began trading on the NASDAQ on 25 July 2014

The Irish drug company makes after-surgery pain treatment and medicine for diabetic foot infections. It raised $58.5 million after pricing 6.5 million American depositary shares at $9 per ADS. It previously expected to raise more money, between $69.6 million and $80.3 million, in a larger offering of shares. Innocoll plans to use the cash it raised to develop its treatments and increase its manufacturing infrastructure. Its shares, which are trading on the Nasdaq exchange under the symbol "INNL," closed flat at $9. During trading hours, the stock fell as low as $8.58 and rose as high as $9.51.

Ocular Therapeutix (OCUL) began trading on the NASDAQ on 25 July 2014

The maker of treatments and therapies for eye diseases raised $65 million after selling 5 million shares at $13 per share. The pricing is below its previously expected range of between $14 and $16 per share. Ocular plans to use the money it raised to complete clinical trials of its treatments, for marketing expenses and to buy manufacturing equipment. Its shares rose 15 cents to $13.15 on the Nasdaq exchange. The shares trade under the symbol "OCUL." The company is based in Bedford, Massachusetts.


Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. The Company’s hydrogel is a bioresorbable formulation of polyethylene glycol (PEG), which when constituted with water takes on a gelatinous consistency. The Company’s product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase III clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase II clinical development for glaucoma and ocular hypertension. These product candidates combine its hydrogel technology with the United States Food and Drug Administration (FDA), approved therapeutic agents with the goal of providing sustained delivery of drug to the eye.


Ste 101, 36 Crosby Drive
United States

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin-25955.55%-
Operating margin-25277.78%-
EBITD margin--
Return on average assets--59.94%
Return on average equity--

Friday, July 25, 2014

Jumei (JMEI) : 2-month performance

El Pollo Loco Holdings (LOCO) began trading on the NASDAQ on 25 July 2014

El Pollo Loco, which serves up Mexican-style dishes, is the latest restaurant chain to soar in its stock market debut. Others, including Zoe's Kitchen Inc., Potbelly Corp. and Noodles & Co., also climbed in their initial public offerings.

The chain, whose headquarters is in Costa Mesa, California, grills chicken in front of customers to make its Mexican-style dishes at its 400 restaurants in Arizona, California, Nevada, Texas and Utah. It raised more than $107 million after pricing 7.14 million shares at $15 per share. It plans to use the cash raised to pay down debt. Shares of El Pollo Loco, which are trading on the Nasdaq exchange under the symbol "LOCO," rose $9.03, or 60.2 percent, to close at $24.03.

El Pollo Loco Holdings, Inc. (EPL) develops, franchises, licenses and operates quick-service restaurants under the name El Pollo Loco and operates under one business segment. The restaurants, which are located principally in California but also in Arizona, Nevada, Texas, and Utah, specialize in flame-grilled chicken in a variety of contemporary Mexican-influenced entrees, including specialty chicken burritos, chicken quesadillas, chicken tortilla soup, Pollo Bowls and Pollo Salads. The Company is a subsidiary of Trimaran Pollo Partners, LLC. At December 25, 2013, the Company operated 168 (133 in the greater Los Angeles area) and franchised 233 (136 in the greater Los Angeles area) El Pollo Loco restaurants.

3535 Harbor Blvd Ste 100
COSTA MESA, CA 92626-1494
United States 

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin6.72%-5.36%
Operating margin14.14%6.63%
EBITD margin-18.05%
Return on average assets5.24%-4.04%
Return on average equity42.72%-29.83%

Online real estate giant Zillow (Z) in reported $2 billion bid for Trulia (TRLA)

Two of the most popular real estate sites in the nation -- Zillow and Trulia -- may combine in a move that would create an online colossus in a tradition-bound industry disrupted by massive technology change in recent years.

Seattle-based Zillow, the leading online site based on the number of users, is making a bid to buy San Francisco-based Trulia, the second most popular site, for as much as $2 billion, according to a report Thursday by Bloomberg that cited unnamed sources. Neither company would comment on the report.

Both sites have brought tremendous changes to the process of buying a home. Trulia has an easy-to-use app that allows potential buyers to shop on their mobile phones, while Zillow has the best-known way for homeowners and virtual lookie-loos to get an estimate of how much a home is worth. But some in the industry worry the combination would harm consumers, leading to less competition and less innovation.

Combined, the company would have more than 80 million unique visitors, according to the market research firm Comscore, and nearly 90 percent of the market.

Trulia's shares jumped more than 32 percent or $13.16 a share on the report, and Zillow's shares were up more than 15 percent or $19.29 a share at the close of the market. Both companies have enjoyed a run-up in stock prices this year.

weekly charts:

"An acquisition like this will have a huge impact, specifically on the home-buying space and particularly for real estate agents in the single family resale business," said Charles Stubbs, chief executive officer of RentPath, whose websites include ApartmentGuide, and Lovely.

It would also create a more formidable competitor to San Jose-based Move Inc., which operates for the National Association of Realtors. was third in unique monthly visitors in March, according to Comscore.

Move declined to comment on the report.

If the acquisition is completed, Zillow swallows a challenger to its business, leaves consumers with one less place to browse for real estate for sale or rent, and real estate agents one fewer place to list homes for sale.

"I don't know that this is a good thing for the consumer," said Myron Von Raesfeld, president of the Santa Clara County Association of Realtors. "I don't think eliminating the options for the consumer ultimately benefits the consumer."

Competition between the companies has led each of them to substantially increase their advertising and improve their websites.

With an acquisition, they can cut their advertising spending significantly, "and no longer be in this ad race" for traffic, said Daniel Kurnos, an analyst with the Benchmark Company.

Trulia also has made a big push on its mobile app, while Zillow has continued to generate traffic with its popular home valuation site. Not long ago it launched a home remodeling web page. Both companies make revenue by charging real estate agents to list property on their sites.

Zillow and Trulia also list homes and apartments for rent.

The acquisition would be one more disruptive event in a real estate marketplace punctuated by rapid change and recent acquisitions.

Trulia acquired Market Leader last year, giving it a tool to help agents track down leads for potential clients. Zillow bought StreetEasy, a New York area real estate site, last year for $50 million.

The acquisition of ZipRealty by Realogy, a franchise that includes many well-known real estate names, was announced this month. ZipRealty is an Emeryville-based company that emphasizes listing, buying and selling real estate online.

"A lot of people in the real estate industry are struggling," ZipRealty's CEO Lanny Baker recently told this newspaper. "They know how to put a sign outside and how to bring in the consumer, but how do they do that online? The big challenge for them is to figure out the digital world."

Another disrupter, Redfin, based in Seattle, is changing the tried and true model in which real estate agents work with brokers to collect commissions on sales of houses. Redfin's agents are salaried and paid according to customer satisfaction, according to the company.

Despite the big traffic numbers generated by Zillow, a substantial amount comes from people using its "Zestimate" tool to see how much their homes, and their neighbors', are worth, said Bradley Safalow of PAA Research. "Half of Zillow's traffic comes from homes that are not for sale. People saying, 'What's my home worth?'"

Safalow said only 15 percent of real estate agents can afford to advertise with the sites.

If the two companies combine, "my expectation is that a lot of brokers will say I'm not going send my listings to you anymore. They might put them on" or stop sharing them with the websites, he said. "I think that's the biggest risk in this merger.''

Sunday, July 20, 2014

Chinese IPOs surge in Shanghai and Shenzhen stock markets

It’s a rare investment that can return 70% in just a few days. But investors are finding exactly that in Chinese initial public offerings this year, thanks in large part to the Chinese government. 
All 58 IPOs making their debuts in China’s Shanghai and Shenzhen stock markets this year have risen by nearly the maximum 44% allowed on the first day of trading. In the following five days, 57 have gone on to average further gains of 24%. The 58th IPO launched Friday.
The eye-popping gains can be credited to China’s financial regulators, who shut down the IPO market for 14 months before reopening it at the start of this year. Before the first listing in January, regulators had added the 44% cap on first-day gains and demanded that companies sell their shares on the cheap, providing the fuel for a first-day pop.
The pent-up demand for IPOs has made them the hottest China commodity in an already volatile stock market mostly filled with fast-trading individuals. The immense appetite, though, has left potential buyers fighting to obtain the new stocks and generated echoes of the late 1990s in the U.S., when buyers scrambled to buy hot technology stocks.
China’s current approval-based IPO system has long been criticized for distorting supply and demand in one of the world’s largest stock markets. Listing aspirants have had to endure an application process that can include roughly 10 rounds of reviews and last as long as several years. There are still 637 companies on the waiting list for approval.
“The regulator has again created a situation where there are more monks than the porridge available,” said Zhang Gang, senior analyst at Central China Capital Securities, using a traditional Chinese saying. “It’s all about giving away more gains to a secondary market dominated by retail investors, but such reforms do have a strong administrative flavor.”

Friday, July 18, 2014

Globant (GLOB) began trading on the NYSE on 18 July 2014

Martin Migoya, Globant CEO and Co-Founder of Globant rings the Opening Bell at The New York Stock Exchange on July 18, 2014 in New York City. 

Globant S.A. is technologies services provider focused on delivering software solutions that leverage technologies and related market trends. The Company combines the engineering and technical rigor of information technology (IT) services providers with the creative approach and culture of digital agencies.


5 rue Guillaume Kroll

Trupanion (TRUP) began trading on the NYSE on 18 July 2014

Trupanion CEO Darryl Rawlings celebrates the company's initial public listing at The New York Stock Exchange on July 18, 2014 in New York City

Trupanion, Inc., is a direct-to-consumer monthly subscription service providing a medical insurance plan for cats and dogs throughout the United States, Canada and Puerto Rico. As of March 31, 2014, the Company’s enrolled pets consisted of approximately 85% dogs and 15% cats. The Company operates in two segments: subscription business and other business. The Company generates revenue in its subscription business segment primarily from subscription fees for its medical plan, which the Company markets to consumers. The Company generates revenue in its other business segment primarily from writing policies for an unaffiliated managing general agent that offers pet insurance and from writing policies under a federal government program. These policies provide different coverage and are subject to materially different terms and conditions than the Trupanion medical plan.


SEATTLE, WA 98107-4607
United States 

Thursday, July 17, 2014

CareDx (CDNA) began trading on the Nasdaq on 17 July 2014

CareDx Announces Pricing of its IPO and Completion of its First Day of Trading
Brisbane, CA July 17, 2014 CareDx, Inc. (NASDAQ: CDNA) announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a price to the public of $10 per share, before underwriter discounts. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock at the initial public offering price to cover over -allotments, if any. CareDx completed its first day of trading today on The NASDAQ Global Market under the ticker symbol "CDNA."

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.


3260 Bayshore Blvd
BRISBANE, CA 94005-1021
United States 

Monday, July 14, 2014

Genocea Biosciences (GNCA) : 5-month performance

Signal Genetics (SGNL) began trading on the NASDAQ on 18 June 2014

  • As of February 13, 2017, Signal Genetics, Inc. was acquired by miRagen Therapeutics, Inc.,  a privately-held biopharmaceutical company, in a reverse merger transaction. 
  • The combined company is named Miragen Therapeutics and trades under the ticker "MGEN."


Signal Genetics, Inc. is a commercial-stage, molecular diagnostic company focused on providing diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. It develops, validates and delivers diagnostic services that enable better patient-care decisions.


NEW YORK, NY 10065
United States

Key stats and ratios

Q1 (Mar '14)2013
Net profit margin-64.70%-50.03%
Operating margin-15.28%-4.55%
EBITD margin--6.90%
Return on average assets-78.99%-66.93%
Return on average equity--

LGI Homes (LGIH) : 8-month performance

Thursday, July 10, 2014

Potbelly (PBPB) plummets on sales warning

  • IPO'd at $14 on 4 Oct 2013
  • dropped the most since its October initial public offering after its annual profit forecast and quarterly sales trailed analysts' estimates.

  • Shares of Potbelly Corp. (PBPB) are falling 20%  on Thursday continuing a decline that began in after-hours trading on Wednesday, following the company's 2014 second quarter sales warning.

    Potbelly, a sandwich, salads, and fresh foods restaurant chain, announced it's expecting a 1.6% decrease in comparable store sales for the second quarter versus a 3% increase from the 2013 second quarter.

    However, the company is expecting an increase in revenue to $83.6 million, up from $78.2 million from the year ago period, but falling short of the $87 million in revenue analysts are expecting.

    Potbelly will announced its 2014 second quarter results after the market closes on August 5.

    Wednesday, July 9, 2014

    The Container Store (TCS) : 8-month performance + earnings

    Shares of the storage and organization products seller TCS  tumbled today, after the company reported late Tuesday fiscal first-quarter earnings and revenue that missed analyst expectations.

    For the quarter ending May 31, CEO Kip Tindell said he was wrong in thinking recent “sluggish” sales trends were all about weather and a shortened-holiday shopping season. Instead, he said consumers in general are in a spending “funk.”

    It’s not the company’s fault, because Tindell said he was confident consumers are as enthusiastic about Container Stores’s brand as they have ever been. Tindell said he was pleased that the company didn’t succumb to consumers’ insistence on deeper discounts.

    And yet the stock is down 48% so far this year, and is headed for the lowest close since it went public on Nov. 1, 2013.

    Wall Street analysts seem to believe the company is just fine. Credit Suisse analyst Gary Balter said long-term investors should use the stock’s weakness as a buying opportunity,  while J.P. Morgan’s Christopher Horvers said he still believes investors will continue to pay a premium, relative to its peers, for the shares.

    Among high-growth retailers that have gone public recently, that Horvers pegged as Container Store’s peers, Fairway Group FWM  has plunged 64% this year, Potbelly (PBPB)  has lost 39% and Sprouts Farmers Market (SFM)  has dropped 17%.

    Container Store is the second seller of discretionary items to blame stingy consumers for disappointing results. Bed Bath & Beyond BBBY  said on June 25 that one of the reasons it missed earnings estimates, and provided a disappointing outlook, was because consumers bumped up the use of coupons. Raymond James analyst Budd Bugatch followed by saying while it might seem “Pollyanna-ish,” investors should be “patient.” Bed Bath & Beyond’s stocks is down 27% this year.

    Meanwhile, Wal-Mart Stores, which Wall Street considers a seller of what people always need, said its sluggish sales weren’t all the consumers’ fault. U.S. CEO Bill Simon said Tuesday the company needed to adjust to changes in the economy and spending habits. Investors seem to agree, as the stock is headed for a sixth-straight gain, and is down just 1.8% this year.

    Thursday, July 3, 2014

    Abengoa Yield (ABY) began trading on the NASDAQ on 13 June 2014

    Abengoa Yield plc owns renewable energy, conventional power, and electric transmission line contracted assets in North America, South America, and Europe. The company's renewable energy assets consist of concentrating solar power plants and concentrating solar power plants. It serves governments and electrical utilities. The company was incorporated in 2013 and is based in Leeds, United Kingdom.


    Abengoa Yield plc is formed to serve as the primary vehicle through which Abengoa, S.A. (Abengoa) will own, manage and acquire renewable energy, conventional power and electric transmission lines and other contracted revenue-generating assets, initially focused on North America (the United States and Mexico) and South America (Peru, Chile, Uruguay and Brazil), as well as Europe (Spain). Abengoa portfolio consists of five renewable energy assets, a cogeneration facility and several electric transmission lines, all of which are fully operational, with the exception of Palmatir and Mojave. In addition, it owns an exchangeable preferred equity investment in Abengoa Concessoes Brasil Holding (ACBH), which is a subsidiary holding company of Abengoa that is engaged in the development, construction, investment and management of contracted concessions in Brazil, consisting mostly of transmission lines.


    United Kingdom

    Key stats and ratios

    Q1 (Mar '14)2013
    Net profit margin-44.75%-0.88%
    Operating margin37.45%52.91%
    EBITD margin-75.17%
    Return on average assets-1.97%-0.04%
    Return on average equity-8.18%-0.30%

    ZS Pharma (ZSPH) began trading on the NASDAQ on 18 June 2014

    • ZS Pharma (ZSPH) is a late-stage biotech developing a treatment for excess potassium (hyperkalemia)
    • Offered 5.0 million shares
    • ZS Pharma was founded in 2008, booked $0 million in sales over the last 12 months. 
    • Coppell, TX-based company 
    • J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.


    ZS Pharma, Inc is a biopharmaceutical company focused on the development and commercialization of selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. The Company’s zirconium silicate technology allows it to create selective ion traps that can reduce toxic levels of specific electrolytes without disturbing the balance of other electrolytes. Its initial focus is on the development of ZS-9, its product candidate in Phase III development for the treatment of hyperkalemia, a life-threatening condition in which elevated levels of potassium in the blood increase the risk of muscle dysfunction, including cardiac arrhythmias and sudden cardiac death. The Company has completed two clinical studies with ZS-9 that together enrolled 843 patients with hyperkalemia, including patients with chronic kidney disease, (CKD), heart failure (HF), diabetes and those on renin-angiotensin aldosterone system (RAAS), inhibitor therapy.


    COPPELL, TX 75019
    United States 

    Key stats and ratios

    Q1 (Mar '14)2013
    Net profit margin--
    Operating margin--
    EBITD margin--
    Return on average assets-189.69%-169.42%

    Zafgen (ZFGN) began trading on the NASDAQ on 19 June 2014

  • Zafgen (ZFGN), a biotech developing a treatment for severe obesity and hunger-related disorders
  • Offered 5.0 million shares 
  • Zafgen was founded in 2005 in Cambridge, MA. 
  • Leerink Partners and Cowen & Company are the joint bookrunners on the deal.

  • Description

    Zafgen, Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity. Beloranib, the Company’s product candidate, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia, or insatiable life-threatening hunger and hunger-related behaviors, in Prader-Willi Syndrome (PWS), craniopharyngioma-associated obesity, and severe obesity in the general population. PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms, including hyperphagia and obesity. Craniopharyngioma is a rare form of benign brain tumor that occurs near the optic nerve, pituitary gland and hypothalamus. Approximately 30% to 50% of cases of craniopharyngioma are diagnosed in childhood and adolescence.


    CAMBRIDGE, MA 02142
    United States 

    Key stats and ratios

    Q1 (Mar '14)2013
    Net profit margin--
    Operating margin--
    EBITD margin--
    Return on average assets-45.00%-57.11%
    Return on average equity--

    Parnell Pharmaceuticals began trading on the NASDAQ on 18 June 2014

    Parnell Pharmaceuticals Holdings Ltd. operates as an integrated pharmaceutical company that develops animal health solutions. It operates in four segments: Companion Animal, Production Animal U.S., Production Animal Rest of World, and Manufacturing Operations. The company's marketed products include reproductive hormone products comprising estroPLAN and GONAbreed that are used in breeding programs to increase pregnancy rates in dairy and beef cows; Zydax, a patented disease-modifying product for the treatment of osteoarthritis (OA) in dogs and horses; Glyde, a nutraceutical product is a combination of glycoaminoglycans for the treatment of OA in dogs; and Tergive, an injectable NSAID that contains carprofen. It is also developing GONADOPRO combination formulation of gonadorelin acetate; PAR081, a propofol-based product for general anesthesia and sedation in dogs and cats; PAR101 to treat laminitis in horses and diabetes in dogs; PAR121 for bone-related diseases and injuries in dogs, cats, and horses; PAR122 for atopic dermatitis and other dermatological conditions; and PAR061, an injectable antibiotic prodrug. The company markets its products in Australia, New Zealand, Singapore, Hong Kong, Dubai, the United States, Canada, the Middle East, and Africa. The company was formerly known as Parnell Pharmaceuticals Holdings Pty Ltd and changed its name to Parnell Pharmaceuticals Holdings Ltd. in April 2014. The company was founded in 1986 and is headquartered in Alexandria, Australia.

    Foresight Energy LP (FELP) began trading on the NYSE on 18 June 2014

    Foresight Energy LP (FELP), an Illinois Basin coal producer backed by billionaire Christopher Cline,  offered 17.5 million shares.  Foresight Energy LP, which was founded in 2005, booked $968 million in sales over the last 12 months. It is based in St. Louis, MO. Barclays, Citi, Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal.


    Foresight Energy LP is an underground coal producer in the United States. The Company operates four underground mining complexes, all in the Illinois Basin region of the United States. The Company’s mining complexes consist of: Williamson Energy, LLC, Sugar Camp Energy, LLC, Hillsboro Energy, LLC and Macoupin Energy, LLC.


    ST. LOUIS, MO 63102
    United States 

    Key stats and ratios

    Q1 (Mar '14)2013
    Net profit margin13.15%1.10%
    Operating margin25.35%13.20%
    EBITD margin-37.92%
    Return on average assets7.33%0.62%
    Return on average equity-13.36%

    Eclipse Resources (ECR) began trading on the NYSE on 20 June 2014


    Eclipse Resources Corporation is an independent exploration and production company engaged in the acquisition and development of oil and natural gas properties in the Appalachian Basin. As of March 31, 2014, the Company had assembled an acreage position approximating 227,230 net acres in Eastern Ohio. Its Ordovician-aged Utica Shale is an unconventional reservoir comprised of organic-rich black shale, with most production occurring at vertical depths between 6,000 and 10,000 feet. The richest and thickest concentration of organic-carbon content is present within the Point Pleasant layer of the Lower Utica formation. The Company has evaluated the results of 56 wells that have been publicly disclosed within the Utica Core Area, 13 of which it has drilled or participated in. The Marcellus Shale consists of organic-rich black shale, with most production occurring at vertical depths between 5,000 and 8,000 feet.


    United States

    Key stats and ratios

    Q1 (Mar '14)2013
    Net profit margin-74.44%-336.61%
    Operating margin-4.86%-175.42%
    EBITD margin--108.88%
    Return on average assets-6.29%-6.82%
    Return on average equity-10.83%-10.96%